^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HLA G-targeted CAR-T immunotherapy

    Related drugs:
    1m
    A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=117 --> 31
    Enrollment closed • Enrollment change
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • HLA-G (Major Histocompatibility Complex, Class I, G)
    |
    BRCA mutation
    |
    cyclophosphamide • fludarabine IV • IVS-3001
    1year
    CAR001: A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Ever Supreme Bio Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2years
    A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=117, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2029 --> Dec 2029
    Trial completion date • CAR T-Cell Therapy • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • HLA-G (Major Histocompatibility Complex, Class I, G)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • IVS-3001
    2years
    CAR001: A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Ever Supreme Bio Technology Co., Ltd.
    New P1/2 trial
    over2years
    A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=117, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jun 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • HLA-G (Major Histocompatibility Complex, Class I, G)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • IVS-3001
    3years
    A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=117, Not yet recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2029 --> Jun 2029 | Initiation date: Jun 2023 --> Feb 2023
    Trial completion date • Trial initiation date • CAR T-Cell Therapy • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • IVS-3001
    3years
    A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=117, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • CAR T-Cell Therapy • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • IVS-3001